Cargando…

Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma

BACKGROUND: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including m(6)A, m(5)C, m(1)A RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lei, Liu, Wen-Ke, Du, Xiao-Wei, Liu, Xiang-Li, Li, Gao, Yao, Yao, Han, Tao, Li, Wen-Ya, Gu, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333141/
https://www.ncbi.nlm.nih.gov/pubmed/32647676
http://dx.doi.org/10.21037/atm-20-3744
_version_ 1783553688989597696
author Sun, Lei
Liu, Wen-Ke
Du, Xiao-Wei
Liu, Xiang-Li
Li, Gao
Yao, Yao
Han, Tao
Li, Wen-Ya
Gu, Jia
author_facet Sun, Lei
Liu, Wen-Ke
Du, Xiao-Wei
Liu, Xiang-Li
Li, Gao
Yao, Yao
Han, Tao
Li, Wen-Ya
Gu, Jia
author_sort Sun, Lei
collection PubMed
description BACKGROUND: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including m(6)A, m(5)C, m(1)A RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and stem cell regeneration. However, there are few studies on lung adenocarcinoma. This study aims to explore the clinical value of RNA methylation for lung adenocarcinoma. METHODS: We summarized thirty-one RNA methylation regulators. The training set was obtained from The Cancer Genome Atlas (TCGA) database, and the test set was obtained from the Gene Expression Omnibus (GEO) database. The Wilcoxon test was used to analyze the expression of RNA methylation regulators. We constructed tumor subgroup models and risk models based on the expression of those regulators. Principal component analysis (PCA) and the receiver operating characteristic (ROC) confirmed the accuracy of the models. Real-time polymerase chain reaction (PCR) validates the results in vitro. RESULTS: Most RNA methylation regulators had distinct expressions in tumor tissues and adjacent tissues (P<0.05). All the models showed high predictive performance (AUC: 0.65–0.82), and the five-year survival of patients in each group was statistically different (P<0.05). The patients in the high-risk group were more likely to have a higher stage, more lymph node metastases, and distant metastases, showing a poor clinical outcome. Patients with high expression of NOP2 or HNRNP were more likely to have a poorly differentiated in vitro experiment. CONCLUSIONS: With our study, we found that the expressions of most RNA methylation regulators were significantly different in cancer and para-cancerous tissues. Different molecular phenotypes constructed by RNA methylation regulators can be independent risk factors for the prognosis of lung adenocarcinoma. Our study demonstrates the critical role of RNA methylation in lung adenocarcinoma, and it is expected to supply a reference for the prognostic stratification and treatment strategy development of lung adenocarcinoma.
format Online
Article
Text
id pubmed-7333141
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-73331412020-07-08 Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma Sun, Lei Liu, Wen-Ke Du, Xiao-Wei Liu, Xiang-Li Li, Gao Yao, Yao Han, Tao Li, Wen-Ya Gu, Jia Ann Transl Med Original Article BACKGROUND: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including m(6)A, m(5)C, m(1)A RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and stem cell regeneration. However, there are few studies on lung adenocarcinoma. This study aims to explore the clinical value of RNA methylation for lung adenocarcinoma. METHODS: We summarized thirty-one RNA methylation regulators. The training set was obtained from The Cancer Genome Atlas (TCGA) database, and the test set was obtained from the Gene Expression Omnibus (GEO) database. The Wilcoxon test was used to analyze the expression of RNA methylation regulators. We constructed tumor subgroup models and risk models based on the expression of those regulators. Principal component analysis (PCA) and the receiver operating characteristic (ROC) confirmed the accuracy of the models. Real-time polymerase chain reaction (PCR) validates the results in vitro. RESULTS: Most RNA methylation regulators had distinct expressions in tumor tissues and adjacent tissues (P<0.05). All the models showed high predictive performance (AUC: 0.65–0.82), and the five-year survival of patients in each group was statistically different (P<0.05). The patients in the high-risk group were more likely to have a higher stage, more lymph node metastases, and distant metastases, showing a poor clinical outcome. Patients with high expression of NOP2 or HNRNP were more likely to have a poorly differentiated in vitro experiment. CONCLUSIONS: With our study, we found that the expressions of most RNA methylation regulators were significantly different in cancer and para-cancerous tissues. Different molecular phenotypes constructed by RNA methylation regulators can be independent risk factors for the prognosis of lung adenocarcinoma. Our study demonstrates the critical role of RNA methylation in lung adenocarcinoma, and it is expected to supply a reference for the prognostic stratification and treatment strategy development of lung adenocarcinoma. AME Publishing Company 2020-06 /pmc/articles/PMC7333141/ /pubmed/32647676 http://dx.doi.org/10.21037/atm-20-3744 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Sun, Lei
Liu, Wen-Ke
Du, Xiao-Wei
Liu, Xiang-Li
Li, Gao
Yao, Yao
Han, Tao
Li, Wen-Ya
Gu, Jia
Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
title Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
title_full Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
title_fullStr Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
title_full_unstemmed Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
title_short Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
title_sort large-scale transcriptome analysis identified rna methylation regulators as novel prognostic signatures for lung adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333141/
https://www.ncbi.nlm.nih.gov/pubmed/32647676
http://dx.doi.org/10.21037/atm-20-3744
work_keys_str_mv AT sunlei largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT liuwenke largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT duxiaowei largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT liuxiangli largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT ligao largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT yaoyao largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT hantao largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT liwenya largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma
AT gujia largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma